Iovance Biotherapeutics, Inc.
Clinical trials sponsored by Iovance Biotherapeutics, Inc., explained in plain language.
A biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Hacked immune cells take on tough cancers Results expected Sep 2027 (estimated)
-
Immune cells from your own tumor could fight advanced melanoma
Disease control OngoingThis study tests an experimental therapy called lifileucel for people with advanced melanoma that has spread or cannot be removed by surgery and has worsened after standard treatments. About 100 adults will receive their own tumor-fighting immune cells (TILs) grown in a lab. The …
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a Patient's own immune cells beat childhood cancers that Won't quit?
Disease control OngoingThis early-stage trial tests a treatment made from a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL). Doctors remove a piece of the tumor, grow the immune cells in a lab, and then infuse them back into the patient to attack the cancer. The study includes 4…
Phase 1 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC